New antibiotic cocktail takes first step in human safety trial
NCT ID NCT06079775
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and drug interactions of an experimental oral antibiotic combination (QPX7831 plus ceftibuten) in 53 healthy adults. The goal was to see how the body processes the drugs and whether they cause side effects. Results will help decide safe doses for future studies in patients with bacterial infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- xeruborbactam oral prodrug (QPX7831) and ceftibuten
- What this could lead to
- If successful, this could lead to a new oral combination treatment for bacterial infections that are resistant to current antibiotics.
- What could go wrong
- This is an early Phase 1 study in only 53 healthy people, so it cannot yet show if the drug works against infections. Side effects may emerge in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMAX
Adelaide, South Australia, 5000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test curb antibiotic overuse in sick kids?
- New drug CTX-187 takes aim at stubborn bacterial infections
- Can smarter antibiotic choices curb superbugs in liver disease?
- New bedside test could help doctors fine-tune antibiotics in real time
- Vaccine Follow-Up: how long does protection last in babies?
- New antibiotic vabomere tested in kids for first time